Identification of predictive factors for early relapse in patients with unresectable stage III NSCLC receiving consolidation durvalumab after concurrent chemoradiation

被引：0
|
作者：
Yeo, Chang Dong
Kang, Hye Seon
Kim, In Kyoung
Lee, Sang Haak
Kim, Jin Woo
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-6757
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6757
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in US patients with unresectable stage III NSCLC following concurrent chemoradiation
    Haque, R.
    McGary, E.
    Yang, M.
    Liu, R.
    Suga, J. M.
    Chen, L. H.
    Zhu, Z.
    Simmons, D.
    Hsieh, K.
    Cotarla, I.
    Sakoda, L.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E50 - E50
  • [32] Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation
    Shukla, Nikhil A.
    Hanna, Nasser H.
    LUNG CANCER MANAGEMENT, 2020, 9 (01)
  • [33] Implementation of Durvalumab-Maintenance Therapy after Chemoradiation for Patients with inoperable stage III NSCLC in Germany
    Kaesmann, L.
    Taugner, J.
    Eze, C.
    Roengvoraphoj, O.
    Belka, C.
    Manapov, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S143 - S144
  • [34] SPOTLIGHT real-world study: Outcomes with or without consolidation durvalumab (D) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC
    Whitaker, R. M.
    Cai, L.
    Wang, A.
    Qiao, Y.
    Chander, P.
    Mooradian, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S111 - S111
  • [35] First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC
    Faehling, Martin
    Planchard, David
    Cho, Byoung Chul
    Gray, Jhanelle Elaine
    Paz-Ares, Luis G.
    Ozguroglu, Mustafa
    Villegas, Augusto E.
    Daniels, Davey B.
    Vicente, David
    Murakami, Shuji
    Hui, Rina
    Kurata, Takayasu
    Chiappori, Alberto
    Lee, Ki Hyeong
    Gu, Yu
    Wadsworth, Catherine
    Dennis, Phillip A.
    Antonia, Scott Joseph
    de Wit, Maike
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 120 - 120
  • [36] Potential risk factors of pneumonitis associated with consolidation pembrolizumab after chemoradiation in unresectable NSCLC patients.
    Ahmed, Shahid Sattar
    Durm, Greg Andrew
    Donatelli, John
    Yao, Huan
    Liu, Yongmei
    DesRosiers, Colleen
    Liu, Ziyue
    Kong, Feng Ming
    Hanna, Nasser H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [37] PACIFIC: a double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC
    Schulz, C.
    Laack, E.
    Wolff, T.
    Rueckert, A.
    Reck, M.
    Faehling, M.
    Fischer, J. R.
    de Wit, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 270 - 270
  • [38] Outcomes and Treatment Patterns for Recurrence following Concurrent Chemoradiation and Consolidation Immunotherapy in Unresectable Stage III NSCLC: A Multi-Center Study
    Young, Philip
    Sharp, John
    Michaels, Kenan
    Fultineer, Kylie
    Hall, Richard
    Lynch, Alia
    Thomas, Marie
    Owen, Dwight
    Gentzler, Ryan
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E58 - E59
  • [39] Pulmonary toxicities after chemoradiation followed by durvalumab for stage III NSCLC: a real setting
    Nicolet, C.
    Briot, N.
    Amoyal, C.
    Chevalier, C.
    Jeandidier, C.
    Kaderbhai, C.
    Foucher, P.
    Westeel, V.
    Martin, E.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1069 - S1070
  • [40] Radiological changes and patterns of progression in unresectable stage III NSCLC treated with concurrent chemoradiotherapy (CCRT) and durvalumab
    Patel, Rianne
    Abdulwahid, Danya
    Bayman, Neil
    Coote, Joanna
    Cove-Smith, Laura
    Fenmore, Jackie
    Harris, Margaret
    Neal, Hilary
    Taylor, Paul
    Sheikh, Hamid
    Woolf, David
    Chan, Clara
    Faivre-Finn, Corinee
    LUNG CANCER, 2023, 178 : S59 - S59
12345